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Abstract
Oxidative stress plays a significant role in allergic airway inflammation. Supplementation with
alpha-tocopherol (alone or combined with ascorbate/vitamin C) has been assessed as an
intervention for allergic airway diseases with conflicting results. Enhancing levels of airway
antioxidants with oral supplements has been suggested as an intervention to protect individuals
from the effect of inhaled oxidants, although it is unclear whether supplementation changes
tocopherol or vitamin C levels in both serum and airway fluids. Our objective was to obtain pilot
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safety and dosing data from 14 allergic asthmatic volunteers examining the effect of daily
combination oral therapy with 500 mg alpha-tocopherol (αT) and 2 g vitamin C for 12 wk. We
examined serum and airway fluid and cellular levels of alpha- and gamma-tocopherol (γT) and
vitamin C to plan for future studies of these agents in asthma and allergic rhinitis. Six volunteers
completed 12 wk of active treatment with αT and vitamin C and 8 completed placebo. Blood and
sputum samples were obtained at baseline and at 6 wk and 12 wk of therapy and were analyzed for
αT, γT, and vitamin C levels in the serum, sputum supernatant, and sputum cells. Combination
treatment increased serum vitamin C and significantly decreased sputum αT and serum γT levels.
No changes were found in sputum supernatant or sputum cell vitamin C or serum αT levels in the
active treatment group. In conclusion, supplementation with αT and high-dose vitamin C does not
augment vitamin C levels in the respiratory-tract lining fluid.
Due to its role in oxygen exchange and its exposure to the external environment, the lung is
particularly susceptible to oxidant stress. There is a growing body of evidence that redox
homeostasis is an essential element in airway inflammation that is central to the
pathophysiology of asthma, environmental lung disease, and smoking-related disorders
(Cross et al., 2002). In studies focused on asthma, nutritional deficiencies in antioxidants
like vitamin E, vitamin C, and selenium have been linked to asthma prevalence (Gilliland et
al., 2003), including large epidemiologic studies associating lower serum levels of vitamin C
with increased risk of wheezing (Schwartz & Weiss, 1990), While much remains to be
learned about dietary factors and asthma pathogenesis, several studies do suggest that
enhancing antioxidant and anti-inflammatory defenses is a logical target for development of
complementary and alternative medicine (CAM) therapies for use by persons with allergic
diseases.
The data on antioxidant supplementation in asthma is mixed. Several investigators have
reported that vitamin C supplementation decreases bronchial reactivity to methacholine and
histamine (Zuskin et al., 1973; Mohsenin et al., 1983) and exercise-induced bronchospasm
(Schachter & Schlesinger, 1982). A double-blinded, placebo-controlled trial with Nigerian
asthmatics taking 1 g/day of vitamin C showed decreased rate and severity of asthma
exacerbations. (Anah et al., 1980) However, more recent studies have found no clinical
benefit on asthma with regular dietary supplementation with vitamin C (Fogarty et al.,
2003). Studies evaluating the effect of α-tocopherol (vitamin E) supplementation have also
had mixed results, with one study finding no clinical benefit in asthma patients after 6 wk of
supplementation (Pearson et al., 2004), and another study finding no benefit on the
incidence of pulmonary symptoms in COPD patients after 3 yr of supplementation
(Rautalahti et al., 1997).
In addition to its action as a direct radical scavenger, vitamin C protects lipids from
oxidative stress and can transform the oxidized product of α-tocopherol, α-tocopheroxyl,
back to its original reduced form in vitro. These observations have led to investigation of
combination therapy using vitamin C and α-tocopherol in a number of disease states,
including environmental lung disease. In a series of reports on the use of combination
antioxidant interventions, several groups have found that such combination therapy
attenuated loss of lung function following natural or experimental ozone exposure compared
to placebo controls (Romieu et al., 2002) (Trenga, Koenig et al., 2001). Of a cohort of
normal volunteers who undertook an antioxidant-depleted diet prior to ozone challenge,
those who received supplementation with vitamin E and vitamin C for 1 wk displayed a
trend toward reduced decreases in forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) after ozone challenge compared to placebo controls (Samet et al., 2001).
Our group has also reported that levels of vitamin C in respiratory-tract lining fluids of
asthmatics sampled by induced sputum are diminished relative to normal volunteers
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(Kongerud, et al., 2003). This observation is consistent with the hypothesis that asthmatics
have increased susceptibility to the effects of ozone, and the idea that antioxidant
supplementation would protect asthmatics from the effect of ozone challenge on decreased
lung function. However, it is unclear how effective supplementation is in increasing
antioxidant levels in persons who consume a vitamin-sufficient diet. In anticipation of
undertaking a study of the effect of high-dose vitamin C and α-tocopherol on the effect of
ozone in asthmatics, we conducted a randomized, double-blinded, two-group, placebo-
controlled Phase I pilot dosing study to determine whether supplementation with 500 mg α-
tocopherol and 2 g vitamin C on a daily basis for 12 wk increases serum, repiratory-tract
linining fluid, and sputum-cell vitamin C, α-tocopherol, and γ-tocopherol levels in a cohort
of allergic asthmatics sampled by induced sputum (IS).
MATERIALS AND METHODS
Subjects
Adult subjects between the ages of 18 and 50 yr were recruited through use of
advertisements placed on Clintrials.gov and Center for Environmental Medicine, Asthma
and Lung Biology (CEMALB) web sites. Potential subjects were also identified from the
CEMALB database of subjects who have expressed interest in participating in studies. In
total, 15 allergic, asthmatic volunteers were recruited and randomized to one of the
following treatment groups: placebo tocopherol and placebo vitamin C, or 500 mg
tocopherol and 2 g vitamin C.
Inclusion into the study required oxygen saturation of >94% at baseline, and blood pressure
between 90 and 150 mm systolic and between 60 and 100 mm diastolic. Atopy was
demonstrated by positive immediate skin test response to one of the following allergen
mixes: two species of house dust mite (Dermatophagoides farinae and Dermatophagoides
Pteryonnisuius), cockroach, tree mix, grass mix, weed mix, mold mix 1, mold mix 2, rat,
mouse, guinea pig, rabbit, cat, or dog.
Moderate to severe persistent asthma was defined according to NHLBI definitions including
history one of the following:
1. Episodic wheezing, chest tightness, or shortness of breath consistent with asthma
symptoms at least 1 time per week that affects activity.
2. Asthma symptoms occurring at night or during sleep at least once per week.
3. Measured FEV1 or FVC <80% of predicted.
4. Physician-diagnosed moderate or severe persistent asthma that was currently
controlled with maintenance medication that includes inhaled corticosteroids with
or without the addition of long-acting beta agonists.
Exclusion criteria included pregnancy or currently nursing a baby; inability to abstain from
nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, antihistamines, or anticoagulants
for the length of the study; a current diagnosis of anemia or abnormal blood counts or
clotting times at screening; and known vagal response to venipuncture. Volunteers were also
excluded if they had any chronic medical condition considered by the Principal Investigator
(PI) as a contraindication to receiving the alpha-tocopherol and ascorbate supplements,
including significant cardiovascular disease, diabetes, chronic renal disease, chronic thyroid
disease, kidney disease, or coagulation defects. Volunteers were also asked to refrain from
taking vitamin supplements or other dietary supplements for the length of the study
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This study was reviewed and approved by the Committee for the Protection of the Rights of
Human subjects of the University of North Carolina (UNC). All study subjects signed a
consent form prior to any study procedures. Participants then underwent an assessment of
general health including a health history questionnaire, physical exam, measurement of
baseline circulating antioxidant levels, measurement of baseline safety laboratory tests, lung
function assessment, and symptom scoring prior to receiving the supplements.
Study Design
This was a randomized, double-blinded, placebo-controlled study of 500 mg α-tocopherol
and 2000 mg vitamin C, with each supplement orally administered daily for 12 wk in
asthmatic volunteers. The two supplements were kindly provided as a gift from Yasoo
Health, Inc. (Johnson City, TN), and were then distributed by the UNC investigational drug
pharmacy. Subjects were instructed to take each supplement at the same time each day.
Primary endpoints included serum levels of γT, αT, and vitamin C, and the levels of these in
sputum supernatant and sputum cells. The study was powered on the assumption that dosing
of asthmatics with high levels of antioxidants would normalize the lower levels of vitamin C
present in the airways of asthmatics, as noted by Kongerud et al. (2003). We estimated a
sample size of 20 per group for a 12-wk dosing study, based on determinations of effect size
and variability from previous vitamin C studies (Kongerud et al., 2003). After having
completed dosing in 14 asthmatic volunteers, interim analysis was undertaken to reconfirm
original power estimates to establish the effectiveness of changing antioxidant levels in the
serum, respiratory-tract lining fluid (RTLF), and sputum cells after 6 and 12 wk of
supplementation. Secondary endpoints included changes in sputum cellularity, symptom
scores derived from a multidomain symptom questionnaire (see later description), and
changes in lung function measures.
Blood samples were collected at baseline and at 6 wk and 12 wk after the initial dose of
supplementation and immediately placed on ice. These blood samples were analyzed for
serum levels of α-tocopherol, γ-tocopherol, and vitamin C. Sputum was collected at baseline,
at 6 wk, and at 12 wk. Sputum was assessed for levels of α-tocopherol, γ-tocopherol, and
vitamin C in the sputum supernatant and sputum cells. Furthermore, the types of
inflammatory cells composing the sputum were compared before and after supplementation.
Lung function and symptom score measures were made on a weekly basis. Individual
subject participation lasted approximately 14 wk and required 14 visits to the study facility.
Participants were compensated for their time and expenses.
Symptom Score Questionnaire
All subjects filled out a symptom questionnaire before randomization and on a weekly basis.
The questionnaire had the participant score any symptoms they were experiencing on a scale
of 0 (none) to 3 (severe), and were given definitions of mild, moderate, and severe. There
were 12 symptom choices, including malaise, fatigue, shortness of breath, cough, myalgia,
chills, fever, headache, nausea, vomiting, indigestion/stomachache, and unusual bleeding/
bruising. The minimum possible score on the questionnaire was 0, and maximum possible
score was 36.
Allergy Testing
Skin allergy testing was performed before randomization. Skin testing was performed using
skin test reagents from Greer Laboratories, and included extracts for dust mites (D.
pteronyssinus and D. farinae), tree mix, weed mix, grass mix, mold, cat, dog, rat, mouse,
rabbit, guinea pig, and cockroach. Antigen solution was placed on the anterior forearms of
test subject using a specialized 8-pronged applicator and was left on the skin for 15 min
before the test was read. Allergic individuals developed indurations corresponding to
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individual allergens, and the diameters in millimeters of the resulting indurations were
measured and traced. A positive allergic response is quantified as a resultant wheal diameter
that is equal to or larger than the positive control wheal (histamine). A negative control is
also included in the battery to aid in reading the test.
Induction of Sputum and Differential Cell Counts
Sputum induction and processing were performed according to previously published
methods with some modifications (Alexis et al., 2001). In brief, subjects inhaled increasing
concentrations (3%, 4%, and 5%) of hypertonic saline for 7 min each, for a total of 21 min.
Manual selection of plug material was weighed and treated with 0.1% dithiothreitol (DTT,
in Dulbecco’s phosphate-buffered saline [DPBS]) that contained 25 μM desferoxamine
(DFA) for cell dispersion. DFA was added as a precaution to prevent redox recycling.
Differential cell counts were analyzed from Romanowski (Diff-Quik)-stained slides, based
on 400 cells, and expressed as a percentage of total nonsquamous nucleated cells.
Acceptable slides had a minimum of 50% viability (trypan blue staining) and less than 20%
squamous epithelial cell content.
Sputum and Serum Processing for Antioxidant Analysis
Sputum—Following DTT dispersion, filtration, and sample centrifugation, the cell pellet
was recovered and then equally distributed into two tubes, one marked for ascorbate
analysis, the other for tocopherol analysis. For the ascorbate analysis tube, 500 μl of 10%
metaphosphoric acid (MPA) containing 25 μM desferoxamine (DFA) in DPBS was added
directly to the cell pellet followed by storage at −80°C. The tocopherol tube was only
centrifuged, the supernatant was discarded, and the pellet was stored at −80°C. The sputum
supernatant fraction was also equally distributed into two tubes, one for vitamin C and one
for tocopherol analysis. Seventy percent MPA was added to the vitamin C tube (10% MPA
and 25 μM DFA final concentrations) followed by centrifugation for 20 min, and the
supernatant was stored at −80°C. The tocopherol tube was only centrifuged and the
supernatant was stored at −80°C.
Serum
Blood was collected in serum separator tubes and allowed to settle in the tubes for 30 min.
The tubes were then centrifuged at 1500 × g for 15 min at 4°C. Serum was equally
distributed into two tubes (600 μl each). The tocopherol tube was immediately stored at
−80°C. The vitamin C tube was treated with 10% MPA containing 25 μM DFA (100 μl 10%
MPA + 175 μM DFA), then stored at −80°C.
Analysis of Tocopherols
Quantitation of Tocopherols—αT and γT were measured by a high-performance liquid
chromatography (HPLC) assay with electrochemical detection (Christen et al., 2002).
Briefly, tocopherols were extracted from serum, sputum cells, and sputum supernatant using
a mixture of methanol/hexane (2:5, v/v). All extractions were carried out in the presence of
0.8 mM butylated hydroxytoluene. After centrifugation at 1000 × g for 10 min at 4°C, the
top hexane layer was collected and evaporated under N2, and the dried residue was
redissolved in ethanol. Tocopherols were separated on a 150 × 4.6 mm, 5-μm Supelcosil
LC-18-DB column, and eluted with 95:5 (v/v) methanol/water with final 25 mM lithium
acetate (pH 4.75) at a flow rate of 1.2 ml/min. Tocopherols were monitored by coulometric
detection (model Coulochem II, ESA, Inc., Chelmsford, MA) at 300 (upstream) and 500 mV
(downstream electrode) using a model 5011 analytical cell.
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Analysis of Vitamin C
MPA-treated samples were centrifuged (27,000 × g, 20 min at 4°C). Serum, sputum
supernatants, and sputum cells were assayed for vitamin C using amperometric detection
using an LC-4B detector (Bioanalyticial Systems, West Lafayette, IN) (Kutnink, Hawkes et
al., 1987). Each sample was analyzed for about 9.0 min. A glassy carbon electrode was used
and the potential was 0.5 V. Standards were run from 39 ng/ml to 10,000 ng/ml. The lower
end of the level of detectability is between 18 and 39 ng/ml; samples above 5500 ng/ml are
diluted and rerun. The detector sensitivity was set at 100 nA/V. The flow was 1.5 ml/min.
The mobile phase was aqueous and consisted of 0.04 M sodium acetate, 0.54 mM
ethylenediamine tetraacetic acid (EDTA), 2.5 mM dodecyltriethyl ammonium phosphate,
and 6% methanol, with the pH adjusted to 4.75.
Statistical Analysis
To account for differences in baseline antioxidant levels in the experimental groups, we first
calculated the difference between the 6-wk (Δ6,0) or 12-wk (Δ12,0) measurements and the
baseline measurements for each individual where Δ12,0 = Y12 − Y0 and Δ6,0 = Y6 − Y0,
respectively. We then tested the differences between the active and placebo groups with a
two-sample t-test when the equality of variances was satisfied; when the equality of
variances was not satisfied, a Satterthwaite t-test was adopted. Differences were considered
statistically significant if p < .05. To improve the statistical power, we also employed a
multivariate regression analysis to take advantage of the repeated observations per
individual (at baseline, wk 6, and wk 12).
For the analysis of inflammatory cells in the sputum, the total number of cells isolated from
each individual was added over the 12-wk period of observation. The total number of cells
from those individuals in the active group versus the number for placebo group were
compared using a two-sample t-test. The same procedure was applied to the measurements
of FEV1. For the symptom score measurements, we grouped each individual’s symptom
scores into two categories: no symptoms (scores 0–3) and mild–moderate symptoms (score
>4). We then applied a logistic regression to compare the total symptom scores of those
subjects in the active versus placebo groups, adjusting for other covariates that include




Fourteen of 15 volunteers completed this randomized double-blinded placebo-controlled
Phase I study in which volunteers consumed 2 capsules per day for 12 wk of 500 mg α-
tocopherol and 2 g vitamin C, or placebo α-tocopherol and placebo vitamin C. One of the
subjects randomized to the treatment group dropped out at wk 6 due to the development of
cystitis. This was reported as an adverse event. Upon further review of the subject’s history,
she was found to have a history of mild, intermittent right lower quadrant discomfort. This is
the same symptom that was reported during the study period. She reported that her personal
physician suspected that she had cystitis, and was therefore excluded from the study due to
the possibility that vitamin C therapy may aggravate the cystitis.
There were some notable differences in the characteristics of the active and placebo groups
at baseline (Table 1): On average, the subjects in the active treatment group were older and
had a lower baseline FEV1. The active group was also composed of more subjects using
inhaled corticosteroids for asthma therapy.
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Figure 1 depicts the serum and sputum supernatant vitamin C levels in the placebo and
active groups. In the active group, the serum vitamin C levels increased after starting
supplementation with a mean level of 21,660 ng/ml at 6 wk and a mean level of 17,760 ng/
ml at 12 wk. The serum vitamin C levels at 6 and 12 wk showed a large degree of variation
within the active group (Figure 1a). A simple comparison of active and placebo groups,
without adjusting for baseline differences, demonstrated a statistically significant difference
in serum vitamin C levels between the active and placebo groups following both 6 and 12
wk (p = .046 and p = .018, respectively). A more rigorous assessment of the differences in
the 12-wk or 6-wk to baseline serum vitamin C levels was made for the active and placebo
groups: This difference reached statistical significance for wk 6 (p = .043) and almost
reached statistical significance for wk 12 (p = .069). Despite the observation that high-dose
supplementation was associated with increased serum levels of vitamin C, these levels did
not translate to increased levels in the sputum supernatant. The difference in wk 12 and
baseline sputum supernatant vitamin C levels was not statistically different between the
active and placebo groups (p = .604) (Figure 1b). Vitamin C did not appear to be
sequestered into sputum cells either: The difference in wk 12 and baseline sputum cell
vitamin C levels was not statistically different between the active and placebo groups (p = .
429), although this result should be interpreted with caution due to the small number of
samples analyzed at wk 12 in the active group.
Alpha-Tocopherol
Figure 2 depicts the serum, sputum supernatant, and sputum-cell levels of alpha-tocopherol.
Compared to baseline, the serum αT levels increased after 12 wk of supplementation in the
active group, but the rise in the active group was not statistically significant when compared
to the placebo group (p = .18) (Figure 2a). Unexpectedly, α-tocopherol supplementation
decreased levels in the sputum supernatant in the active group (Figure 2b). A two-sample t-
test did not detect a statistically significant difference (p = .105) but the repeated measure
approach showed that the reduction in levels in the active group almost reached statistical
significance compared to the placebo group (p = .077). The differences in α-tocopherol
levels in sputum cells between the active and placebo groups did not reach statistical
significance (p = .814).
Gamma-Tocopherol
As previous studies have shown interactions between α-and γ-tocopherol levels in the serum
(Handelman et al., 1985; Clement & Bourre, 1997), we also evaluated the levels of γ-
tocopherol in the serum, sputum supernatant, and sputum cells. We found that γT levels in
the serum significantly dropped in the active group during the 12-wk period of α-tocopherol
supplementation (p = .035) (Figure 3a). However, this drop in serum γT levels did not effect
changes in γT levels in the sputum supernatant of subjects in the active group (p = .22).
Supplementation with α-tocopherol had no effect on sputum cell γT levels in the active
group (p = .979).
Sample Size Estimates for the Supplemented Antioxidants
Based on the variability we found in our samples, we calculated the sample sizes required to
observe a statistically significant difference between active versus placebo antioxidant
supplementation in various physiologic relevant compartments, using the observed serum
and sputum supernatant antioxidant levels in this study. These estimates are calculated based
on a two-sided test with equal variances for the α-tocopherol data, assuming alpha = .05 and
power = 80% and a 1:1 ratio for sample sizes. Due to the different observed variances in
vitamin C levels in the active and the placebo groups, unequal variances were assumed, and
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we used a two-sided Sattherwaite t-test, again assuming alpha = .05 and power = 80% and a
1:1 ratio for sample sizes.
Our initial hypothesis was that supplementation with αT and vitamin C would result in
changes in airway αT and vitamin C levels. Based on the effect sizes seen in this study, we
estimate that we would need 15 persons in each arm to demonstrate a statistically significant
change in serum vitamin C (total n = 30). However, to detect a significant difference in
RTLF vitamin C for our treatment regimen would require 133 volunteers in both the placebo
and treatments groups (total n = 266). If we base a sample size estimate on serum alpha-
tocopherol, we would require 30 volunteers in each group. If we base a sample size estimate
on changes in RTLF α-tocopherol, we would require 19 volunteers in each group to detect a
significant change in α-tocopherol.
Sputum Differential Cell Counts
There was no significant difference in the cumulative total cell count from induced sputum
between the active and placebo groups through wk 12 (p = .36). We also evaluated the types
of inflammatory cells isolated from the sputum. The cumulative numbers of neutrophils,
over the 12-wk period since randomization, were significantly higher in the active group
than in the placebo group (p = .034). There were no significant differences in the cumulative
numbers of eosinophils (p = .45) or macrophages (p = .08) between the active or placebo
groups over the 12-wk period of observation. Table 2 shows total cell counts from induced
sputum at wk 0, wk 6, and wk 12 isolated from subjects in the active and placebo groups and
differential cell counts.
Measures of Lung Function
The FEV1 was determined for each volunteer at baseline and every other week during the
study. There was no significant difference in the cumulative percent predicted FEV1
between the active and placebo groups through wk 12 (p = .42). Symptom scores were also
compared between the active and placebo groups, and no statistically significant difference
was noted between the two groups (p = .93).
DISCUSSION
The rationale for using combination treatment with α-tocopherol and vitamin C to prevent
inflammation and injury of tissues due to oxidative stress is largely based on in vitro
observations that vitamin C can participate in reactions that recycle α-tocopherol after it is
oxidized in cellular redox reactions (Kelly et al., 1995). This may be particularly relevant in
preventing airway inflammation and injury due to ozone exposure. Different research teams
have reported that α-tocopherol and vitamin C combination therapy was effective in
mitigating the effect of ozone-induced lung function decrements in asthmatics (Samet et al.,
2001; Trenga et al., 2001; Romieu et al., 2002; Romieu et al., 2004), or in normal volunteers
after they had undertaken an antioxidant-depleted diet to mimic a state of poor antioxidant
nutritional status (Samet, Hatch et al., 2001). Our group has also found that vitamin C levels
in airway fluids of asthmatics were significantly decreased compared to those of normal
volunteers (Kongerud et al., 2003). Taken together, these observations led to the hypothesis
that combination treatment with α-tocopherol and vitamin C would enhance airway vitamin
C levels in asthmatics, and would protect them from the adverse effects of ozone exposure.
Before committing to a study examining the effect of combination treatment on response of
asthmatics to ozone, we felt it was important to confirm that α-tocopherol and vitamin C
modify airway antioxidant levels. Thus, the primary aim of this dosing study was to
determine whether oral supplementation with 2 g vitamin C and 500 mg α-tocopherol daily
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for 12 wk would increase levels of vitamin C (which we used as a sentinel antioxidant) in
RTLF of asthmatics to levels observed in normal volunteers. We also examined effects of
such supplementation on serum levels of α-tocopherol and vitamin C as well as γ-
tocopherol, a vitamin E isoform with antioxidant and radical-scavenging capabilities.
In designing our study, we used a very generous dose of vitamin C, coupled with a dose of
α-tocopherol employed in other studies in which a protective effect of this intervention had
been reported. Although it is known that vitamin C metabolism is tightly regulated, we
chose this high dose of vitamin C to maximize the likelihood that we would achieve changes
in RTLF vitamin C levels. Data from this pilot study of 14 volunteers indicate that the
combination supplementation regimen does not change vitamin C levels in the RTLF despite
a significant increase in serum vitamin C levels of asthmatic subjects. These observations
led us to the conclusion that protective effects reported by oral supplementation with α-
tocopherol and vitamin C may not be primarily due to changes in airway fluid
concentrations of these molecules. Supporting this conclusion is a report that levels of
airway antioxidants (including tocopherols and vitamin C) do not predict physiologic or
inflammatory responses to ozone challenge (Mudway et al., 2001).
There may be other specific risk factors or populations in which vitamin supplementation
may modify airway levels of antioxidants. Our volunteers were persons with moderate to
severe asthma, most of whom were using inhaled corticosteroids, but were otherwise
generally well nourished and in good health. While persons with asthma per se may not
benefit from antioxidant supplementation, those with nutritional deficiencies may derive
benefit from antioxidant replacement therapy, given the effect of supplementation in
nutritionally impaired volunteers. Genetic factors may also play an important role in
determining effectiveness of antioxidant supplements.
Perhaps the best example of this is a series of studies of children with asthma in Mexico City
conducted by Romieu and colleagues. They assessed the ability of dietary supplementation
of 50 mg/day of vitamin E and 250 mg/day of vitamin C to protect child asthmatics from
ozone-induced exacerbation of disease (Romieu et al., 2004). Overall, there was a
significant protective effect on forced midexpiratory flow rate (FEF25-75) observed in the
entire group of asthmatics, but this effect was much more apparent in those children with the
glutathione-S-transferase M1 (GSTM1) null genotype. There are a number of other studies
that reveal that defects in GSTM1, an antioxidant response protein, and other antioxidant
enzymes regulated by the transcription factor NRF2 are associated with increased risk for
pollutant-induced respiratory disease (Cho et al., 2006; Kensler et al., 2007). It may be that
focused attention on the pharmacokinetics and efficacy of antioxidant supplements in
persons with genetic risk for oxidant injury may demonstrate beneficial effects not observed
in a general population.
The dose of antioxidants used may also impact physiologic responses to ozone challenge or
routine environmental challenges. We did not find any differences in FEV1 or symptom
scores between the active and placebo groups. In another study of normal volunteers who
did not undergo presupplement dietary antioxidant depletion, supplementation with 100 mg/
day α-tocopherol and 500 mg/day vitamin C did not prevent acute responses to ozone
(Mudway et al., 2006). The failure to see protection could be due to possible pro-oxidant
effects of vitamin C seen at oral supplementation doses of 400–500 mg (Cooke et al., 1998,
2003), as the protective studies performed by Romieu, Samet, and colleagues used doses of
250 mg/day. Failure to see protective effects could also be due to higher consumption of α-
tocopherol by high levels of vitamin C. Serum tocopherol levels have been noted to increase
simultaneously with vitamin C supplementation in combination therapy studies using 250
mg/day vitamin C (Samet et al., 2001; Romieu et al., 2002). It is unclear whether a
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potentially pro-oxidant environment created by higher doses of vitamin C could deplete α-
tocopherol levels in various physiologic compartments, accounting for the failure to alter
various parameters of lung function at baseline, or to prevent ozone-induced acute
responses.
As an additional exploratory endpoint, we also examined changes in airway sputum
cellularity across the 12-wk dosing period, primarily to determine whether there had been
any decrease in airway eosinophils, an important inflammatory cell in asthma. While we
observed no change in sputum eosinophils, more neutrophils were recovered in sputum of
those in the active group. This observation is consistent with findings by Samet et al., who
observed that α-tocopherol and vitamin C supplementation in persons who were rendered
antioxidant depleted by use of a specifically deficient diet had increased sputum neutrophils
(Samet et al., 2001). High vitamin C intake also appears to influence the response of
neutrophils to oxidative stress induced by exercise, increasing neutrophil activation, as
reflected by a significant decrease in superoxide dismutase activity in neutrophils recovered
from well-supplemented athletes after exercise. It has also been noted that expression of the
CD11b/CD18 adhesion molecule complex is upregulated in athletes supplemented with
vitamin C (Tauler et al., 2003). As these observations indicate that vitamin C
supplementation may impact neutrophil activity, changes of antioxidant content of cellular
and tissue compartments may be more important venues to study than changes of scavenger
molecules on mucosal surfaces. The failure to see significant changes in sputum-cell
antioxidant concentrations in our study may be primarily due to the limited samples
available for these assays, as the study was not powered on this endpoint.
In conclusion, our pilot data indicate that oral supplementation with α-tocopherol and
vitamin C does increase serum vitamin C, but has no effect on RTLF vitamin C levels.
Supplementation had no effect on serum α-tocopherol and was associated with decreased α-
tocopherol levels on the airway surface. Although it is attractive to hypothesize that
providing oral supplements would augment levels of airway surface antioxidants and thus
protect individuals from the effect of inhaled oxidants, this view is overly simplistic.
Asthmatics may have defective antioxidant transport mechanisms to the extracellular
compartment, and/or have a highly oxidizing airway environment that consumes more
antioxidants than normals. Asthmatics may benefit from topical administration of vitamin C
therapy instead of oral supplementation. Finally, intracellular antioxidant content may be
even more important as this likely protect cells from exogenous oxidants and minimizes
inflammatory processes that are mediated in part by generation of oxidants in situ directly
by inflammatory cells. Thus, future dosing studies of α-tocopherol and vitamin C will need
to focus on assessing intracellular as well as serum and airway fluid compartments to select
appropriate doses for future efficacy studies of antioxidants in asthma.
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Vitamin C levels recovered in the a. serum, b. sputum supernatant, c. sputum cells of
allergic asthmatic subjects. Supplementation augmented serum levels of vitamin C of
subjects in the active treatment group (p = 0.069), yet there was no increase in sputum
supernatant or sputum cell vitamin C levels. Horizontal bar represents the mean.
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Alpha tocopherol levels recovered in the a. serum, b. sputum supernatant, c. sputum cells of
allergic asthmatic subjects. Despite supplementation, subjects in the active treatment group
experienced no change in serum α-tocopherol levels, and a decline in sputum supernatant α-
tocopherol levels (p = 0.01). There were no changes in sputum cell α-tocopherol levels.
Horizontal bar represents the mean.
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Gamma tocopherol levels recovered in the a. serum, b. sputum supernatant, c. sputum cells
of allergic asthmatic subjects. A reduction in serum levels of y-tocopherol was noted in
those subjects who received active supplementation with α-tocopherol and vitamin C (p =
0.035). There were no changes in sputum cell y-tocopherol levels. Horizontal bar represents
the mean.
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TABLE 1
Demographic data of subjects completing the phase I pilot study
Parameter Placebo (n = 8) Active (n = 6)
Age (mean) 25.3 32.5
Gender (% male) 12.5% 33.3%
Race (% white) 87.5% 66.7%
FEV1 (% predicted) 106% 97.7%
Medications
 Percent on inhaled corticosteroids 25% 66.6%
 Percent on leukotriene receptor antagonists 25% 0%
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